Last reviewed · How we verify
NCT05839197: CCGLC-010
A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC
Phase 2 trial testing HAIC in Macrotrabecular Massive Hepatocellular Carcinoma in 38 participants. Status unknown.
15 April 2025
Quick facts
| Lead sponsor | Wan-Guang Zhang |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 38 |
| Start date | 5 May 2023 |
| Primary completion | 15 April 2025 |
| Estimated completion | 15 April 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- HAIC — full drug profile →
- Camrelizumab plus Apatinib — full drug profile →
Conditions studied
- Macrotrabecular Massive Hepatocellular Carcinoma — all drugs for Macrotrabecular Massive Hepatocellular Carcinoma →
Sponsor
Wan-Guang Zhang — full company profile →
Who can join
Adults 18 to 75, any sex, with Macrotrabecular Massive Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-arm, open, multicenter II phase clinical study to compare the efficacy and safety of HAIC combined with Apatinib and Camrelizumab in the treatment of unresectable middle-advanced MTM-HCC.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Small-molecule-based targeted therapy in liver cancer.
Ming Y, Gong Y, Fu X, Ouyang X, et al · · 2024 · cited 6× · PMID 39113358 · DOI 10.1016/j.ymthe.2024.08.001
Verify or expand the search:
- PubMed search for NCT05839197
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of HAIC
Trials testing the same drug.
- NCT07070076 — A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Ther · NA · recruiting
- NCT07466225 — HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion · not yet recruiting
- NCT07340502 — TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular Carcinoma · not yet recruiting
- NCT07105748 — HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA) · Phase 2 · recruiting
- NCT06893887 — Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma · NA · recruiting
Other Wan-Guang Zhang trials
Trials by the same sponsor.
- NCT07077798 — Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection · NA · not yet recruiting
- NCT06822985 — QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma · Phase 1 · not yet recruiting
- NCT05533892 — Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC · Phase 1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05839197 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wan-Guang Zhang
- Last refreshed: 19 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05839197.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing